Abstract. B7 homolog 6 (B7-H6), a member of the B7 family, is as a cell-surface ligand for natural cytotoxicity triggering receptor 3, which is expressed on natural killer cells. It has previously been reported that B7-H6 is undetectable in normal human tissues but is expressed on tumor cells. However, there are few studies focusing on the clinical significance of B7-H6 expression in human carcinoma, with the exception of three studies on ovarian, lung and gastric cancer. The present study investigated the expression of B7-H6 protein in pathologic tissue samples from 305 patients with breast cancer using immunohistochemistry. A high B7-H6 expression level was identified in tissues from 32.13% of patients with breast cancer. These patients were revealed to also exhibit a high expression level of human epidermal growth factor receptor 2, a shorter survival time and a higher rate of lymph node metastasis. Furthermore, the expression level of B7-H6 was not associated with patient age, breast cancer subtype, tumor size, tumor location or estrogen receptor expression. The results of the present study revealed that higher B7-H6 expression level in breast cancer tissues was positively associated with tumor progression. This indicates that B7-H6 is associated with the progression and immunoevasion of human breast cancer; however, the molecular mechanisms underlying this potential effect require further investigation.
Introduction
B7 homolog 6 (B7-H6), a novel member of the B7 family, was identified on tumor cell surfaces in 2009 (1) . B7-H6 has sequence homology with other B7 molecules and similar to other members of the B7 family, B7-H6 contains two extracellular immunoglobulin (Ig) domains; however, the receptor for B7-H6, located on natural killer (NK) cells, was not consistent with other B7 family member receptors, which are located on activated T cells. The receptor for B7-H6 is natural cytotoxicity triggering receptor 3 (NKp30) (1) (2) (3) . NK cells are large granular lymphocytes that produce chemokines and cytokines, and participate in the inflammatory and adaptive immune response (4) . NK cells are also an important part of the innate immune system as they directly kill transformed and virally infected cells (5) .
B7 family members serve an essential role in regulating the immune response against transformed cells through a variety of mechanisms (6) . As specific niches of B7 family members continue to be dissected, their diagnostic and therapeutic potential in tumors is becoming more apparent (6, 7) , and this was highlighted in 2011 by the US Food and Drug Administration approval of an antibody targeting programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 in cancer (8, 9) . The ability to successfully target cell cycle checkpoint regulators has since led to multiple clinical trials investigating antibodies targeting the signaling pathway that the B7 family participate in (10) .
B7-H6 binds to NKp30, triggering antitumor NK cell cytotoxicity and cytokine secretion, thus B7-H6 functions as a tumor-induced self-molecule that alerts the innate immune system to cellular transformation (11, 12) . Previous studies have investigated the association between B7-H6 expression and numerous types of tumor, including 65 cases of lung cancer, 60 cases of gastric cancer and 110 cases of human ovarian cancer (12) (13) (14) . To the best of our knowledge, no previous studies have investigated the clinical significance of B7-H6 protein expression in patients with breast cancer.
The present study aimed to investigate the expression of B7-H6 protein in primary breast cancer by immunohistochemistry (IHC), and to identify the association between B7-H6 expression and the clinicopathological features and survival time of patients with breast cancer. The present study will aid in future studies examining the function of B7-H6 in the tumor immune response. The results of the present study also suggest that B7-H6 may have prognostic and therapeutic value in breast cancer. Table I . Survival data were collected from patient follow-ups. The present study was approved by the Ethics Review Board of The Fourth Hospital of Suzhou and Shanghai Renji Hospital. Written informed consent was obtained from all patients prior to enrollment in the present study.
Construction of the tissue microarray (TMA).
A TMA containing a total of 305 tissue samples was prepared, with core tissue sections (diameter, 1.6 mm) obtained from individual paraffin-embedded breast tumor samples (donor blocks) using a trephine. Sections (4-µm-thick) were cut from each tissue sample, deparaffinized and dehydrated for IHC staining using the procedure described by Chen et al (15) .
IHC staining. Rabbit anti-human B7-H6 polyclonal antibody was purchased from Abcam (Cambridge, UK; cat. no. Ab121794) and was diluted 1:40 to produce a working concentration of 7.5 µg/ml. Kaplan-Meier estimator survival plots were generated, and comparisons between the survival curves were performed using a log-rank test.
Results

B7-H6 protein expression in breast cancer tissues.
In order to determine the expression levels of B7-H6 protein in breast cancer tissues, IHC analysis was performed (Fig. 1) . This revealed that B7-H6 was present in 216/305 (70.82%) of the breast cancer tissues. B7-H6 was predominantly localized in the membrane and cytoplasm of breasts tumor cells. In order to investigate the association between the clinicopathological characteristics of breast cancer and B7-H6 protein expression, the 305 patients were divided into two major subgroups according to their amount of positively stained cells and intensity of B7-H6 staining as follows: Low B7-H6 expression (n=206); and high B7-H6 expression (n=99).
Association between B7-H6 expression and the clinicopathological characteristics of patients with breast cancer.
The association between the clinicopathological characteristics of patients with breast cancer and B7-H6 expression are presented in Table I . This revealed that B7-H6 expression was significantly correlated with nodal metastasis (P=0.003); however, it was not associated with the other clinicopathological parameters, including age, tumor location and tumor size. Furthermore, B7-H6 expression was significantly positively correlated with human epidermal growth factor receptor 2 (HER2) expression status (P<0.0001), a marker of metastasis and predictor of poor prognosis in breast cancer. B7-H6 expression was significantly negatively correlated with progesterone receptor (PR) expression status (P=0.0392), a marker of good prognosis in breast cancer. These results suggest that patients with breast cancer who have higher B7-H6 expression levels have a higher risk of metastases and a poorer prognosis.
Association between B7-H6 expression and post-operative prognosis in patients with breast cancer.
In order to further investigate the prognostic value of B7-H6 expression in human breast cancer, a log-rank test was performed. A total of 51 patient overall survival rates and cumulative survival rate were determined using the Kaplan-Meier estimator method and analyzed using a log-rank test. The survival analysis demonstrated that the overall survival rate of the patient subgroup with low B7-H6 expression was significantly higher compared with the subgroup with high B7-H6 expression (P=0.0394; hazard ratio, 0.1941, 95% confidence interval, 0.04076-0.9238; Fig. 2 ).
Discussion
The B7 family, and their CD28 receptor family of costimulatory and coinhibitory molecules, have previously been demonstrated to serve a potential role in the immune response, and these molecules have been revealed to be effective diagnostic markers and therapeutic targets for tumors (16, 17) . This was highlighted by the approval of the drug ipilimumab and ongoing clinical trials of treatments targeting the PD-L1 signaling pathway (18) . B7-H6, a novel B7 family member, acts as a co-stimulatory ligand that delivers a stimulatory signal to NK cells through its receptor NKp30 (1). The present study aimed to investigate the prognostic value of B7-H6 expression in breast cancer and its potential therapeutic role in tumor adoptive immunotherapy, using TMAs and IHC. The median age of patients with low expression of B7-H6 was 55.11 years (range, 26-94 years). The median age of patients with high expression of B7-H6 was 55.22 years (range, 37-70 years). A Representative immunohistochemical staining of B7 homolog 6 expression in human breast cancer. Negative staining at a magnification of (A) x100 and (B) x400. Weak positive staining at a magnification of (C) x100 and (D) x400. Moderate positive staining at a magnification of (E) x100 and (F) x400. Strong positive staining at a magnification of (G) x100 and (H) x400. It has previously been reported that B7-H6 mRNA was undetectable in a tissue array of 65 normal adult tissues (1), consistent with the absence of the protein on circulating cells isolated from healthy individuals (19) . In contrast, B7-H6 cell surface expression has been observed in cell lines from various tumor types, including lymphoma, leukemia and melanoma (3, 14, 20) . In addition, B7-H6 expression has been detected in tumor tissues, such as gastrointestinal, lung and ovarian (1, (12) (13) (14) 21) . The results of the present study demonstrated that B7-H6 was predominantly localized to the membrane of breast cancer cells in 216/305 (70.82%) of the patients. The pattern of B7-H6 expression, which appears to be limited to tumor cells, is frequently regarded as an example of stress-induced self-recognition by NK cells.
Percentage of patients ----------------------------------------------
B7-H6 was revealed to be a ligand of NKp30 on NK cells, which delivers an activating signal into NK cells (1) . NKp30 consists of a single IgV domain in its extracellular region, a unique structural feature of the CD28 family (22) . Another ligand of NKp30 is HLA-B associated transcript, which is a nuclear protein involved in the tumor protein p53 signaling pathway and apoptosis induction following DNA damage-induced cellular stress (23, 24) . NKp30 was previously revealed to mediate antitumor effects in gastrointestinal stromal tumors and lymphoid leukemia (25, 26) . Numerous previous studies have indicated that the B7-H6-NKp30 signaling pathway is implicated in antitumor activity by stimulating primary NK cells to produce interleukin-2 and interferon-γ (IFN-γ), thus enhancing cytotoxic activity (1, 21) .
The present study investigated the theory that B7-H6 is able to facilitate the elimination of tumor cells by interacting with its receptor NKp30, thus serving a role in antitumor immunity. Previous in vitro studies have also suggested that B7-H6 may be useful for treatment to target tumor cells expressing B7-H6 (3, 19, 27) . Incubation of lymphoma cells with a fusion protein containing B7-H6 and 7D8, an antibody that recognizes CD20, enhanced NK cell activation and cytotoxicity in vitro (28) . In the present study, the analysis of 305 tissue samples from patients with breast cancer did not suggest that B7-H6 has an antitumor function. However, the significant positive correlation identified between B7-H6 expression and lymph node metastasis indicates that B7-H6 may participate in tumor progression and development. Furthermore, a significant positive correlation was identified between B7-H6 protein expression and HER2 expression status, an important maker of poor breast cancer prognosis, recurrence and metastasis.
Similarly to other B7 family members, B7-H6 may exist as a surface/cytosolic molecule in tumor cells and as a soluble molecule in the peritoneal fluid (21) . The soluble from of B7-H6 has been detected in the serum of patients with malignant melanoma, neuroblastoma and ovarian carcinoma (3, 27, 29) . Previous studies have identified elevated levels of soluble B7-H6 in the blood sera of patients with gram-negative sepsis compared with healthy control individuals (23, 24) . Furthermore, the serum concentration of soluble B7-H6, which was detected by disintegrin and metalloprotease (ADAM)-10 and ADAM-17, was associated with the downregulation of NKp30 and inhibited NK cell functions in vitro by impairing IFN-γ production (3, 29) . This indicates that high expression levels of B7-H6 in breast cancer tissues may contribute to cancer cell immunoevasion.
The present study, to the best of our knowledge, demonstrated for the first time the clinical significance of B7-H6 expression in breast cancer, and revealed that B7-H6 protein expression was positively associated with breast cancer metastasis, supporting the hypothesis that B7-H6 expression is involved in the progression of human breast cancer. The present study revealed the possibility that B7-H6 serves a role in tumor immunoevasion and may be a potential target for tumor therapy in the future.
